COST-EFFECTIVENESS ANALYSIS OF ADJUVANT OSIMERTINIB IN RESECTED EGFR-MUTATED EARLY-STAGE NON-SMALL CELL LUNG CANCER IN THAILAND. (2025). Proceedings of the International Conference on Public Health, 9(1), 45-67. https://doi.org/10.17501/24246735.2024.9105